Insys operating loss narrows to $9.11 million in August; revenue down

By Caroline Salls

Pittsburgh, Oct. 2 – Insys Therapeutics, Inc. reported a $9.11 million loss from operations for August on $2.23 million in net revenue, according to it monthly operating report filed Wednesday with the Securities and Exchange Commission.

In comparison, the company posted an $11.4 million loss from operations for July on $3.56 million in net revenue.

The net loss for August was $200,535, narrowing significantly from an $11.36 million July net loss.

In addition, Insys had $55.12 million in cash and cash equivalents as of Aug. 31, up from $37.55 million at the end of July.

The specialty pharmaceutical company is based in Phoenix. The company filed bankruptcy on June 10 in the U.S. Bankruptcy Court for the District of Delaware under Chapter 11 case number 19-11292.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.